Promising Antihypertensive Gains Approval

BMI View: Regulatory approval of azilsartan was a much-needed development to help restore confidence in Takeda's research and development (R&D) portfolio, as the company is relying on the success of a number of pipeline drugs to counteract the expected entry of generic competition on a number of its core products. Most notably, the patent expiry of the blockbuster diabetes drug Actos (pioglitazone) in 2011 will result in significant revenue loss.

To read the full article, please choose one of the following options: